OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Milhem on the Utility of RP1 in Solid Tumors

February 25th 2022

Mohammed Milhem, MBBS, MBBS, discusses the utility of vusolimogeneoderparepvec in solid tumors.

Dr. Wang on Potential Adverse Effects of Ibrutinib in MCL

February 24th 2022

Michael Wang, MD, discusses potential adverse effects associated with ibrutinib in patients with mantle cell lymphoma.

Dr. Oh on the Evolving Treatment Landscape in CLL

February 24th 2022

Stephen Oh, MD, PhD, discuses the evolving treatment landscape of chronic lymphocytic leukemia.

Dr. Barzi on Utilizing VEGF Inhibitors Plus Immunotherapy in MSS mCRC

February 24th 2022

Afsaneh Barzi, MD, PhD, discusses the combination of VEGF inhibitors and immunotherapy in microsatellite stable metastatic colorectal cancer.

Dr. Kahl on the Potential of Zanubrutinib in the Frontline Treatment of CLL

February 24th 2022

Brad S. Kahl, MD, discusses the potential for zanubrutinib in the frontline treatment of chronic lymphocytic leukemia.

Dr. Abrams on Next Steps for Cabozantinib/Atezolizumab Combo in MSS/MMRp CRC

February 23rd 2022

Thomas A. Abrams, MD, discusses the next steps for exploration of cabozantinib plus atezolizumab in the treatment of microsatellite stable and mismatch repair proficient colorectal cancer.

Dr. Wang on Sequencing Oral Agents in MCL

February 23rd 2022

Michael Wang, MD, discusses the sequencing of oral therapies in mantle cell lymphoma.

Dr. Lowentritt on a Real-World Analysis of Apalutamide and Enzalutamide in mCSPC

February 23rd 2022

Benjamin H. Lowentritt, MD, FACS, discusses the real-world analysis of apalutamide and enzalutamide in metastatic castration-sensitive prostate cancer.

Dr. Martin on the Patient Population of the CARTITUDE-1 Study in R/R Multiple Myeloma

February 23rd 2022

Thomas G. Martin, MD, discusses the patient population of the phase 2 CARTITUDE-1 study in relapsed/refractory multiple myeloma.

Dr. Moore on BCMA-Mutation Testing in Ovarian Cancer

February 23rd 2022

Kathleen Moore, MD, discusses current standard of care in treating ovarian cancer.

Dr. Abdou on the Significance of the DESTINY-Breast03 Trial in HER2-Positive Breast Cancer

February 21st 2022

Yara Abdou, MD, discusses the significance of the phase 3 DESTINY-Breast03 trial in HER2-positive breast cancer.

Dr. Iyengar on Trastuzumab Deruxtecan in HER2-Low Breast Cancer

February 21st 2022

Neil M. Iyengar, MD, discusses the use of fam-trastuzumab deruxtecan-nxki in HER2-low breast cancer.

Dr. Leal on the Utilization of PD-1/PD-L1 Inhibitor Monotherapy in Lung Cancer

February 21st 2022

Ticiana Leal, MD, discusses the utilization of PD-1 and PD-L1 inhibitor monotherapy in lung cancer.

Dr. Choueiri on the Follow-Up Analysis of KEYNOTE-564 in RCC

February 19th 2022

Toni Choueiri, MD, discusses the 30-month follow-up analysis of the phase 3 KEYNOTE-564 trial in renal cell carcinoma.

Dr. Petrylak on the Utilization of Enfortumab Vedotin in MIBC

February 18th 2022

Daniel P. Petrylak, MD, discusses the utilization of enfortumab vedotin-ejfv in patients with muscle-invasive bladder cancer (MIBC).

Dr. Iacovelli on Efficacy Findings From the ARIES Trial in Urothelial Cancer

February 18th 2022

Roberto Iacovelli, MD, PhD, discusses efficacy findings from the phase 2 ARIES trial in urothelial cancer.

Dr. Saad on the Efficacy of First-Line Olaparib Plus Abiraterone in mCRPC

February 17th 2022

Fred Saad, MD, FRCS, discusses the efficacy of olaparib plus abiraterone acetate as first-line treatment in metastatic castration-resistant prostate cancer.

Dr. Merseburger on the Efficacy of Continuing Enzalutamide in mCRPC

February 17th 2022

Axel Merseburger, MD, PhD, discusses results from the phase 3b PRESIDE trial in metastatic castration-resistant prostate cancer.

Dr. Armstrong on Findings From a Post-Hoc Analysis of the ARCHES Trial in mHSPC

February 17th 2022

Andrew J. Armstrong, MD, MSc, discusses findings from a post-hoc analysis of the phase 3 ARCHES trial in metastatic hormone-sensitive prostate cancer.

Dr. Chatzkel on Future Treatment Options in Bladder Cancer

February 17th 2022

Jonathan A. Chatzkel, MD, discusses the future treatment options in bladder cancer.